Hemagglutinin virus-like particles incorporated with membrane-bound cytokine adjuvants provide protection against homologous and heterologous influenza virus challenge in aged mice
Authors:
Open Access
- 11 May 2023
- journal article
- research article
- Published by Springer Nature in Immunity & Ageing
- Vol. 20 (1) , 1-14
Abstract
Background: Current influenza vaccines deliver satisfactory results in young people but are less effective in the elderly. Development of vaccines for an ever-increasing aging population has been an arduous challenge due to immunosenescence that impairs the immune response in the aged, both quantitatively and qualitatively. Results: To potentially enhance vaccine efficacy in the elderly, we investigated the immunogenicity and cross-protection of influenza hemagglutinin virus-like particles (HA-VLP) incorporated with glycosylphosphatidylinositol (GPI)-anchored cytokine-adjuvants (GPI-GM-CSF and GPI-IL-12) via protein transfer in aged mice. Lung viral replication against homologous and heterologous influenza viruses was significantly reduced in aged mice after vaccination with cytokine incorporated VLPs (HA-VLP-Cyt) in comparison to HA-VLP alone. Enhanced IFN-γ+CD4+ and IFN-γ+CD8+ T cell responses were also observed in aged mice immunized with HA-VLP-Cyt when compared to HA-VLP alone. Conclusions: Cytokine-adjuvanted influenza HA-VLP vaccine induced enhanced protective response against homologous influenza A virus infection in aged mice. Influenza HA-VLP vaccine with GPI-cytokines also induced enhanced T cell responses correlating with better protection against heterologous infection in the absence of neutralizing antibodies. The results suggest that a vaccination strategy using cytokine-adjuvanted influenza HA-VLPs could be used to enhance protection against influenza A virus in the elderly.Keywords
Funding Information
- National Institute of Allergy and Infectious Diseases (75N93019C00017, 75N93019C00017, 75N93019C00017, 75N93019C00017, 75N93019C00017)
This publication has 67 references indexed in Scilit:
- Virus-Like Particle Vaccine Containing Hemagglutinin Confers Protection against 2009 H1N1 Pandemic InfluenzaClinical and Vaccine Immunology, 2011
- Limited efficacy of inactivated influenza vaccine in elderly individuals is associated with decreased production of vaccine-specific antibodiesJournal of Clinical Investigation, 2011
- Influenza Virus-Like Particles Containing M2 Induce Broadly Cross Protective ImmunityPLOS ONE, 2011
- Preclinical and Clinical Development of Plant-Made Virus-Like Particle Vaccine against Avian H5N1 InfluenzaPLOS ONE, 2010
- Incorporation of membrane-bound, mammalian-derived immunomodulatory proteins into influenza whole virus vaccines boosts immunogenicity and protection against lethal challengeVirology Journal, 2009
- Virus-like Particle (VLP) Lymphatic Trafficking and Immune Response Generation After Immunization by Different RoutesJournal of Immunotherapy, 2009
- Incorporation of Membrane-Anchored Flagellin into Influenza Virus-Like Particles Enhances the Breadth of Immune ResponsesJournal of Virology, 2008
- GM-CSF DNA: An adjuvant for higher avidity IgG, rectal IgA, and increased protection against the acute phase of a SHIV-89.6P challenge by a DNA/MVA immunodeficiency virus vaccineVirology, 2007
- Virus-Like Particle Vaccine Induces Protective Immunity against Homologous and Heterologous Strains of Influenza VirusJournal of Virology, 2007
- Incorporation of Glycosylphosphatidylinositol-Anchored Granulocyte- MacrophageColony-Stimulating Factor or CD40 Ligand Enhances Immunogenicity of Chimeric Simian Immunodeficiency Virus-Like ParticlesJournal of Virology, 2007